---
title: "Adamax"
canonical_url: https://peptidelibrary.app/library/adamax
description: "Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Adamax

Adamax (also called Adamantane-modified Semax) is a synthetic Semax analog in the ACTH fragment analog class. Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.

Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established.

Also known as: Adamantane-modified Semax.

Categories: Cognitive, Experimental.

## Classification

- Type: Synthetic Semax analog / nootropic research
- Mechanism class: ACTH fragment analog
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.

Targets: Melanocortin pathways, BDNF-related signaling (proposed).

Origin: Synthetic adamantane-modified ACTH(4–10) analog.

## Properties

- Sequence: Ac-MEHFPGP-Adam-NH2
- Molecular formula: C50H69N11O11S
- Molecular weight: ≈1033 g/mol
- Half-life: Not established; designed for improved stability compared with Semax

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. 1997. Human study (early or uncontrolled). Population: Adults in the acute period of ischaemic stroke (n=30, with 80 conventionally treated controls). Faster recovery of neurological, especially motor, function reported. Research on a related compound, not this one. Limitations: Studied an analog, not Adamax itself [Source](https://pubmed.ncbi.nlm.nih.gov/11517472/)
2. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. 2018. Human study (early or uncontrolled). Population: Adults after ischaemic stroke (n=110, semax and non-semax subgroups). Higher plasma BDNF levels and better motor and Barthel scores reported. Research on a related compound, not this one. Limitations: Studied an analog, not Adamax itself [Source](https://pubmed.ncbi.nlm.nih.gov/29798983/)

## Safety

Side effects: Human safety profile not established; Possible headache or stimulation based on peptide class reports; Possible irritation depending on route.

Risks: Not FDA approved; No published study of Adamax is indexed in PubMed; Designer peptide with inconsistent supplier identifiers; Unregulated products may be mislabeled or contaminated; Long term safety not established.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Adamax is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Adamax?

Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established.

### What are the side effects of Adamax?

Adamax has no controlled human safety data, so its side-effect profile is not well established. Effects recorded on this profile include possible headache or stimulation based on peptide class reports and possible irritation depending on route. This is reference information, not medical advice.

### How does Adamax work?

Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.

### Is Adamax FDA approved?

No. Adamax is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Adamax?

Reported half-life for Adamax is Not established; designed for improved stability compared with Semax. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Adamax?

Adamax has the sequence Ac-MEHFPGP-Adam-NH2, giving a chain of 4 amino acids. Its molecular formula is C50H69N11O11S.

### What peptides are similar to Adamax?

Compounds most often compared with Adamax include Semax, N-Acetyl Semax Amidate, Selank and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
